Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$17.00 USD
+0.05 (0.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $17.01 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.00 USD
+0.05 (0.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $17.01 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
Zacks News
Integra Announces Preliminary Q4 Results, Share Buyback Plan
by Zacks Equity Research
Integra (IART) projects fourth-quarter 2019 revenues at or near the low end of its previously-announced guidance.
Here's Why You Should Retain Integra LifeSciences Stock Now
by Zacks Equity Research
Investors can hold on to Integra LifeSciences (IART) stock in their portfolio owing to solid prospects.
IART vs. TCMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
IART vs. TCMD: Which Stock Is the Better Value Option?
Integra LifeSciences' (IART) Earnings Top Estimates in Q3
by Zacks Equity Research
We are upbeat about the year-over-year revenue growth in Integra LifeSciences' (IART) Codman Specialty Surgical segment.
Integra LifeSciences (IART) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 4.62% and 0.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra Buys Rebound Therapeutics to Boost Neurosurgery Line
by Zacks Equity Research
Integra (IART) believes, Rebound's MIS technological arm will widen its neurosurgical pipeline within Codman Specialty Surgical space.
IART or GMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
IART vs. GMED: Which Stock Is the Better Value Option?
Integra LifeSciences' Organic Growth Strong on New Products
by Zacks Equity Research
Gaining traction from product unveilings and an improved sales force performance, Integra LifeSciences (IART) expects rapid organic growth in the second half of 2019.
Why Is Integra (IART) Down 1% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) Beats on Q1 Earnings, Ups FY20 EPS Guidance
by Zacks Equity Research
Medtronic (MDT) displays improved performances at CER, banking on growth across all major segmental businesses as well as geographies.
IART or GMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
IART vs. GMED: Which Stock Is the Better Value Option?
Moving Average Crossover Alert: Integra LifeSciences
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
IART vs. ABMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
IART vs. ABMD: Which Stock Is the Better Value Option?
Integra Lifesciences' (IART) Earnings Top Estimates in Q2
by Zacks Equity Research
We are upbeat about Integra LifeSciences' (IART) year-over-year revenue growth across key business segments.
Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 12.31% and 2.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra Partners AI-Driven Data Analytics Firm in Wound Care
by Zacks Equity Research
Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.
Veracyte (VCYT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
IART vs. ABMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
IART vs. ABMD: Which Stock Is the Better Value Option?
Integra LifeSciences' Organic Growth Strong on New Products
by Zacks Equity Research
Banking on product unveilings and a better sales force performance, Integra LifeSciences (IART) pins hopes on accelerated organic growth in the second half of 2019.
Integra (IART) Down 4.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold On to Integra LifeSciences Stock
by Zacks Equity Research
Investor confidence is still high on growth prospects of Integra LifeSciences (IART).
Integra LifeSciences Rides on Product Launch, Faces Rivalry
by Zacks Equity Research
Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.
Integra LifeSciences (IART) Q1 Earnings Beat, Margins Rise
by Zacks Equity Research
Integra LifeSciences' (IART) quarterly performance is majorly hurt by the company's exit from the transition services agreements covering Western Europe.